ArticleJournal of translational medicine2015

CCI-779 (Temsirolimus) exhibits increased anti-tumor activity in low EGFR expressing HNSCC cell lines and is effective in cells with acquired resistance to cisplatin or cetuximab.

Franziska Niehr et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.